DBV Technologies Initiates
Phase III Study of Viaskin Peanut in
Peanut-Allergic Patients One to Three Years of Age
DBV Technologies Reports First Half 2017 Financial Results
Citi’s 12th Annual Biotech ConferenceBoston, MA, USA
EAACI (European Academy Allergy and Clinical Immunology) ConferenceMessukeskus Helsinki, Helsinki, Finland
The AAAAI (American Academy of Allergy Asthma & Immunology) Annual Meeting took place in Atlanta from March 3rd to 6, 2017.